Stockscreener 앱 받기
63.84
3.64%
-2.41
전일 마감가:
$66.25
열려 있는:
$66.45
하루 거래량:
1.57M
Relative Volume:
0.62
시가총액:
$8.90B
수익:
$181.74M
순이익/손실:
$-143.97M
주가수익비율:
-45.93
EPS:
-1.39
순현금흐름:
$9.60M
1주 성능:
-1.12%
1개월 성능:
-1.27%
6개월 성능:
+248.85%
1년 성능:
+235.65%
1일 변동 폭
$63.69
$66.73
1주일 범위
$63.33
$68.44
52주 변동 폭
$9.57
$76.76
Arrowhead Pharmaceuticals Inc Stock (ARWR) Company Profile
명칭
Arrowhead Pharmaceuticals Inc
전화
626-696-4702
주소
177 E COLORADO BLVD, PASADENA, CA
ARWR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ARWR
Arrowhead Pharmaceuticals Inc
|
63.84 | 9.24B | 181.74M | -143.97M | 9.60M | -1.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Arrowhead Pharmaceuticals Inc Stock (ARWR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-06-05 | 개시 | Goldman | Neutral |
| 2023-12-04 | 개시 | BofA Securities | Buy |
| 2023-09-19 | 개시 | Citigroup | Neutral |
| 2023-07-21 | 개시 | TD Cowen | Outperform |
| 2023-05-12 | 다운그레이드 | SVB Securities | Outperform → Market Perform |
| 2023-04-26 | 개시 | SMBC Nikko | Outperform |
| 2023-04-12 | 업그레이드 | SVB Securities | Market Perform → Outperform |
| 2023-03-21 | 개시 | Bernstein | Mkt Perform |
| 2022-09-09 | 개시 | Morgan Stanley | Equal-Weight |
| 2022-05-11 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2022-01-19 | 재개 | Goldman | Buy |
| 2021-08-06 | 재확인 | Chardan Capital Markets | Buy |
| 2021-06-04 | 재개 | Robert W. Baird | Neutral |
| 2021-02-05 | 재확인 | H.C. Wainwright | Buy |
| 2020-12-21 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2020-12-16 | 개시 | UBS | Buy |
| 2020-11-19 | 개시 | Citigroup | Buy |
| 2020-05-13 | 개시 | RBC Capital Mkts | Outperform |
| 2020-05-08 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2020-04-15 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2020-03-24 | 업그레이드 | SVB Leerink | Underperform → Mkt Perform |
| 2020-03-17 | 개시 | Goldman | Neutral |
| 2020-01-21 | 개시 | SVB Leerink | Underperform |
| 2019-12-13 | 개시 | Oppenheimer | Perform |
| 2019-11-29 | 재확인 | Chardan Capital Markets | Buy |
| 2019-11-27 | 재확인 | B. Riley FBR | Buy |
| 2019-11-25 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2019-10-24 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2019-10-22 | 재확인 | Chardan Capital Markets | Buy |
| 2019-10-03 | 개시 | Robert W. Baird | Outperform |
| 2018-09-07 | 업그레이드 | B. Riley FBR | Neutral → Buy |
| 2018-09-06 | 재확인 | Chardan Capital Markets | Buy |
| 2018-08-08 | 재확인 | Cantor Fitzgerald | Overweight |
| 2018-07-02 | 재확인 | Chardan Capital Markets | Buy |
모두보기
Arrowhead Pharmaceuticals Inc 주식(ARWR)의 최신 뉴스
Published on: 2026-01-18 16:18:12 - baoquankhu1.vn
Market Catalysts: How cyclical is Arrowhead Pharmaceuticals Incs revenue streamJuly 2025 Chart Watch & Daily Entry Point Alerts - baoquankhu1.vn
10 Health Care Stocks With Whale Alerts In Today's Session - Benzinga
Arrowhead Pharma stock maintains Overweight rating at Cantor Fitzgerald By Investing.com - Investing.com UK
Arrowhead Pharmaceuticals, Inc. $ARWR Shares Acquired by Nordea Investment Management AB - MarketBeat
SG Americas Securities LLC Boosts Stake in Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Piper Sandler maintains an overweight rating on Arrowhead Pharmaceuticals, Inc. (ARWR) - MSN
Arrowhead Pharmaceuticals (ARWR) Stock Analysis: A Biotech Gem with 17% Upside Potential - DirectorsTalk Interviews
Arrowhead Pharma (ARWR) Price Target Raised by Piper Sandler | A - GuruFocus
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Given "Overweight" Rating at Piper Sandler - MarketBeat
Latham Advises on Arrowhead Pharmaceuticals Upsized Offerings of US$625 Million Convertible Senior Notes, and US$200 Million Common Stock and Pre-Funded Warrants - Legal Desire Media and Insights
Arrowhead Pharmaceuticals at Risk: Potential Generic Competition Threatens REDEMPLO’s Market Exclusivity - MSN
Arrowhead Pharmaceuticals Touts Rudemplo Launch, Obesity RNAi Data and $920M Cash at JPM Conference - MarketBeat
Arrowhead Pharmaceuticals Issues Zero-Coupon 2032 Convertible Notes - TipRanks
Arrowhead Pharmaceuticals Signs Multiple Material Agreements - TradingView — Track All Markets
Arrowhead Pharmaceuticals to Participate in Upcoming January 2026 Events - FinancialContent
Fund Flows: Is Arrowhead Pharmaceuticals Inc gaining market shareWeekly Profit Recap & Capital Efficient Trading Techniques - baoquankhu1.vn
Arrowhead Pharmaceuticals prices upsize convertible notes offering to $625M and stock offering at $64.50 - MSN
A shot in the arm for the innovative drug sector! Piper Sandler bets on Arrowhead, the leader in 'gene silencing', predicting a 55% surge in its stock price. - 富途牛牛
Piper Sandler Maintains an Overweight rating on Arrowhead Pharmaceuticals, Inc. (ARWR) - Finviz
Arrowhead Pharmaceuticals Reports Transformative Year-End Results - MSN
Will Arrowhead Pharmaceuticals Inc. stock recover faster than peers2025 Analyst Calls & Weekly Setup with High ROI Potential - ulpravda.ru
Technical Reactions to ARWR Trends in Macro Strategies - Stock Traders Daily
Oklahoma City NewsThe Oklahoman - FinancialContent
Finance Watch: Aktis Tests 2026 IPO Waters With Year’s First Offering, Raising $318m - Citeline News & Insights
Assessing Arrowhead Pharmaceuticals (ARWR) Valuation After REDEMPLO Approvals And New Obesity Trial Data - Yahoo Finance
Arrowhead’s ARO-DIMERPA Trial Advances in Mixed Hyperlipidemia: What Investors Should Watch - TipRanks
Arrowhead Pharmaceuticals Launches Major Equity and Notes Offerings - TipRanks
Arrowhead Pharmaceuticals (NASDAQ: ARWR) prices equity and 0% 2032 convertible notes offerings - Stock Titan
Will Arrowhead Pharmaceuticals Inc. (HDP1) stock outperform benchmarksChart Signals & Advanced Technical Analysis Signals - ulpravda.ru
Assessing Arrowhead Pharmaceuticals (ARWR) Valuation After Obesity Trial Progress And New REDEMPLO Approvals - Sahm
Will Arrowhead Pharmaceuticals Inc. stock remain a Wall Street favoriteWeekly Earnings Recap & Weekly Market Pulse Updates - ulpravda.ru
How Arrowhead Pharmaceuticals Inc. (HDP1) stock moves in volatile trading sessions2025 Trading Volume Trends & Technical Pattern Based Signals - ulpravda.ru
Can Arrowhead Pharmaceuticals Inc. stock surprise with earnings upsidePortfolio Gains Summary & Daily Stock Trend Watchlist - ulpravda.ru
Will Arrowhead Pharmaceuticals Inc. (HDP1) stock hit Wall Street targets2025 Price Momentum & Weekly High Momentum Picks - ulpravda.ru
Portfolio Shifts: Can Arrowhead Pharmaceuticals Inc. stock surprise with earnings upsideShare Buyback & Risk Managed Investment Signals - ulpravda.ru
ARWR: Joint Management by Jefferies and JPMorgan in Recent Offering - GuruFocus
Arrowhead Pharmaceuticals prices $625 million convertible notes offering By Investing.com - Investing.com Nigeria
Arrowhead Pharmaceuticals Prices Upsized Offerings of Convertible Senior Notes, Common Stock and Pre-Funded Warrants - BioSpace
Arrowhead Pharmaceuticals (ARWR) Unveils $625M Convertible Notes Offering - GuruFocus
Arrowhead Pharmaceuticals Shares Early RNAi Obesity Data, Highlights Visceral Fat Drops and Combo Potential - MarketBeat
Arrowhead Pharmaceuticals prices $625 million convertible notes offering - Investing.com
Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses Interim Results From Obesity Candidates and Advances in Treatment ApproachesSlideshow (NASDAQ:ARWR) 2026-01-07 - Seeking Alpha
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Price Target Raised to $85.00 - MarketBeat
ARWR: Goldman Sachs Raises Arrowhead Pharma's Price Target to $8 - GuruFocus
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Shares Gap DownHere's What Happened - MarketBeat
Arrowhead Pharmaceuticals (ARWR) details $200M stock offering and $500M 2032 convertible notes - Stock Titan
Arrowhead Pharma (ARWR) Sees Target Price Boost by Morgan Stanley | ARWR Stock News - GuruFocus
Arrowhead Pharmaceuticals shares down 7.8% after co announces stock sale, convertible bond offering - marketscreener.com
Arrowhead Pharmaceuticals Announces NMPA Approval of REDEMPLO® (plozasiran) for Familial Chylomicronemia Syndrome (FCS) in China - BioSpace
Bernstein reiterates Market Perform rating on Arrowhead Pharma stock By Investing.com - Investing.com Canada
Arrowhead Pharmaceuticals Inc (ARWR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Arrowhead Pharmaceuticals Inc 주식 (ARWR) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Hamilton James C | Chief Medical Officer |
Jan 05 '26 |
Sale |
63.11 |
40,164 |
2,534,661 |
171,958 |
| Anzalone Christopher Richard | Chief Executive Officer |
Jan 02 '26 |
Sale |
66.10 |
13,187 |
871,703 |
3,792,739 |
4.73%
0.92%
자본화:
|
볼륨(24시간):